Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Asymchem Laboratories Tianjin Co's revenue per share for the
three
months ended in Mar. 2026 was $0.36.
Asymchem Laboratories Tianjin Co's revenue per share for the trailing twelve months (TTM) ended in Mar. 2026 was $1.39.
Warning Sign:
Asymchem Laboratories Tianjin Co Ltd revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Asymchem Laboratories Tianjin Co was 15.60% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was -12.70% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 10.90% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 22.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Asymchem Laboratories Tianjin Co's Revenue per Share or its related term are showing as below:
ASLTY'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -12.7 Med: 23.1 Max: 54.3
Current: -12.7
During the past 13 years, Asymchem Laboratories Tianjin Co's highest 3-Year average Revenue Per Share Growth Rate was 54.30% per year. The lowest was -12.70% per year. And the median was 23.10% per year.
ASLTY's 3-Year Revenue Growth Rate is ranked worse than 70.35% of 769
companies
in the Biotechnology industry
Industry Median: 3.1
vs ASLTY: -12.70
Asymchem Laboratories Tianjin Co (OTCPK:ASLTY) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Asymchem Laboratories Tianjin Co Revenue per Share Related Terms
Asymchem Laboratories Tianjin Co Revenue per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asymchem Laboratories Tianjin Co Revenue per Share Chart
ASLTY vs VRTX, REGN, ALNY: Revenue per Share Comparison
For the Biotechnology subindustry, Asymchem Laboratories Tianjin Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asymchem Laboratories Tianjin Co PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Asymchem Laboratories Tianjin Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Asymchem Laboratories Tianjin Co's PS Ratio falls into.
Asymchem Laboratories Tianjin Co Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.39
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asymchem Laboratories Tianjin Co (ASLTY) has a Revenue per Share of $1.39 as of Mar. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Asymchem Laboratories Tianjin Co and its competitors. According to the industry distribution chart, Asymchem Laboratories Tianjin Co ranks #541 out of 769 companies in the Biotechnology industry, placing it in the top 70.4%.
Is Asymchem Laboratories Tianjin Co's Revenue per Share too high?
Asymchem Laboratories Tianjin Co's current Revenue per Share is $1.39. The Biotechnology industry median Revenue per Share is 3.10. Asymchem Laboratories Tianjin Co's value of $1.39 is 55.2% below this industry median. Based on the distribution chart, Asymchem Laboratories Tianjin Co ranks #541 out of 769 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Asymchem Laboratories Tianjin Co has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Asymchem Laboratories Tianjin Co's Revenue per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Asymchem Laboratories Tianjin Co ranks #541 out of 769 companies for Revenue per Share. This places Asymchem Laboratories Tianjin Co in the lower half of its industry. The industry median Revenue per Share is 3.10. Asymchem Laboratories Tianjin Co's value of $1.39 is 55.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Biotechnology company?
The median Revenue per Share among Biotechnology companies is 3.10, based on 769 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Asymchem Laboratories Tianjin Co's current Revenue per Share of $1.39 is 55.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Asymchem Laboratories Tianjin Co and its competitors. For the Biotechnology industry, the median Revenue per Share is 3.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Asymchem Laboratories Tianjin Co's current Revenue per Share is $1.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asymchem Laboratories Tianjin Co stock overvalued right now?
Based on GuruFocus' analysis, Asymchem Laboratories Tianjin Co (ASLTY) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.81, compared to a current price of $7.45 — trading 54.9% above its estimated fair value. The current Revenue per Share is $1.39 and 55.2% below the Biotechnology industry median of 3.10. Asymchem Laboratories Tianjin Co's overall GF Score™ is 69/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Asymchem Laboratories Tianjin Co (ASLTY), the current Revenue per Share is $1.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Asymchem Laboratories Tianjin Co (ASLTY) Overvalued in 2026?
Based on GuruFocus' analysis, Asymchem Laboratories Tianjin Co stock appears to be overvalued.
The current stock price of $7.45 is trading 54.9% above its estimated GF Value™ of $4.81.
GuruFocus considers Asymchem Laboratories Tianjin Co to be Significantly Overvalued.
Key valuation signals for ASLTY:
Revenue per Share: $1.39
GF Value™: $4.81 vs. price of $7.45 (54.9% above fair value)
Industry Position: 55.2% below the Biotechnology median (#541 of 769)
No single metric tells the full story. See the ASLTY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Asymchem Laboratories Tianjin Co Business Description
Asymchem Laboratories Tianjin Co Ltd is a China-based company, a technology-driven provider of Contract Development and manufacturing organization solutions throughout the drug development and manufacturing process. The group provides clinical-stage CDMO solutions, commercial-stage CDMO solutions, and emerging services. Its operations relate to contract development and manufacturing, which focus on innovation and commercial application of pharmaceutical technology. It has geographic areas in the Chinese Mainland and Overseas.
69GF Score
Get the complete analysis for ASLTY
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASLTY has been successfully added to your 
